Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 8:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–648 of 4,708 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Signs and Symptoms, Respiratory Clear all
Terminated Phase 1 Interventional Results available

Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

NCT02408861
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Anal Carcinoma, HIV Infection, Kaposi Sarcoma, Lung Carcinoma, Metastatic Malignant Solid Neoplasm, Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma, Unresectable Solid Neoplasm, HIV-associated Cancers
Interventions
Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Ipilimumab, Nivolumab, Positron Emission Tomography
Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
32
States / cities
La Jolla, California • Los Angeles, California • Sacramento, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Oct 16, 2026, 8:36 PM EDT
Active, not recruiting Phase 2 Interventional

WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)

NCT06967805
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
MTX-463, Placebo
Biological · Other
Lead sponsor
Mediar Therapeutics
Industry
Eligibility
40 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
22
States / cities
Birmingham, Alabama • Phoenix, Arizona • Newport Beach, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 16, 2026, 8:36 PM EDT
Recruiting No phase listed Observational

Health Opportunities and Promoters of Equitable Screening for Lung Cancer

NCT05784922
View directory record Official record
Conditions
Lung Cancer, Smoking Behaviors, Diagnosis
Interventions
Educational Lung Cancer Screening (LCS) Video
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
50 Years to 80 Years
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 16, 2026, 8:36 PM EDT
Completed Not applicable Interventional Results available

Smart Telehealth Exercise Intervention to Reduce COPD Readmissions

NCT03089853
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Neuromuscular electrical stimulation (NMES)
Device
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
40 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 22, 2022 · Synced Oct 16, 2026, 8:36 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Prospective, Epidemiological Study to Assess the Disease Burden of Respiratory Syncytial Virus Associated, Suspected Lower Respiratory Tract Infections in Newborns, From 0 to 2 Years of Age and Risk of Development of Wheeze and Asthma From 0 to 6 Years of Age

NCT01995175
View directory record Official record
Conditions
Respiratory Syncytial Virus
Interventions
Nasal swab sampling, Blood sampling, Diary cards
Procedure · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
Up to 6 Years
Enrollment
2,409 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2021
U.S. locations
9
States / cities
Oakland, California • Sacramento, California • Santa Clara, California + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2022 · Synced Oct 16, 2026, 8:36 PM EDT
Completed Phase 3 Interventional Results available

Acetaminophen Versus Ibuprofen in Children With Asthma

NCT01606319
View directory record Official record
Conditions
Asthma, Wheezing
Interventions
Acetaminophen, Ibuprofen
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
12 Months to 59 Months
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
15
States / cities
Tucson, Arizona • Oakland, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2017 · Synced Oct 16, 2026, 8:36 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Simultaneous RZV and aIIV4 Vaccination

NCT05007041
View directory record Official record
Conditions
Pain, Quality of Life, Injection Site Reaction, Adverse Drug Event
Interventions
FLUAD® Quadrivalent, Fluzone® High-Dose Quadrivalent, SHINGRIX®
Biological
Lead sponsor
Duke University
Other
Eligibility
65 Years and older
Enrollment
267 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
2
States / cities
Baltimore, Maryland • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 11, 2024 · Synced Oct 16, 2026, 8:36 PM EDT
Recruiting Phase 3 Interventional

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

NCT07222566
View directory record Official record
Conditions
Advanced Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC), Metastatic Non Small Cell Lung Cancer, Lung Cancer
Interventions
PF-08634404, Pembrolizumab, Chemotherapy Regimen 1, Chemotherapy Regimen 2
Biological · Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
226
States / cities
Bullhead City, Arizona • Chandler, Arizona • Gilbert, Arizona + 164 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 16, 2026, 8:36 PM EDT
Recruiting Not applicable Interventional

Community Connections Through Native Hawaiian Cultural Values to Strengthen Youth Resilience, Health, and Well-Being

NCT07536256
View directory record Official record
Conditions
Chronic Disease, Adolescent Asthma, Obesity & Overweight, Youth Mental Health, Youth Obesity, Prediabetes, Asthma
Interventions
Community Referral to Kaiona Programs
Behavioral
Lead sponsor
Waianae Coast Comprehensive Health Center
Other
Eligibility
12 Years to 25 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Waianae, Hawaii
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 16, 2026, 8:36 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Evaluate the Safety and Tolerability of Oral Ixazomib in Scleroderma-related Lung Disease Patients

NCT04837131
View directory record Official record
Conditions
Systemic Sclerosis, Scleroderma, Diffuse Systemic Sclerosis, Diffuse Scleroderma, Diffuse Cutaneous Systemic Sclerosis, Diffuse Cutaneous Scleroderma, Progressive Systemic Sclerosis, Progressive Scleroderma, Scleroderma, Systemic, Scleroderma, Diffuse, Scleroderma;Progressive, Systemic Sclerosis, Diffuse, Systemic; Sclerosis, Progressive, Scleroderma of Lung, Scleroderma With Pulmonary Involvement, Systemic Sclerosis Pulmonary, Systemic Sclerosis With Lung Involvement, Interstitial Lung Disease, Pulmonary Fibrosis Interstitial
Interventions
Ixazomib
Drug
Lead sponsor
Michael M. Pham
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 6, 2025 · Synced Oct 16, 2026, 8:36 PM EDT
Not listed Not applicable Interventional

Systematic Team Approach to Guide Early Mobilization in Surgical Intensive Care Unit Patients

NCT01363102
View directory record Official record
Conditions
Muscle Weakness, Critical Illness, Respiratory Insufficiency
Interventions
SOMS
Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 85 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
3
States / cities
Boston, Massachusetts • Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 17, 2016 · Synced Oct 16, 2026, 8:36 PM EDT
Completed Phase 3 Interventional Results available

Safety Evaluation of Repeat Placement of the S8 Sinus Implant in Chronic Sinusitis Patients With Nasal Polyps (ENCORE)

NCT03358329
View directory record Official record
Conditions
Chronic Sinusitis, Nasal Polyposis
Interventions
S8 Sinus Implant
Combination Product
Lead sponsor
Intersect ENT
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
9
States / cities
Sacramento, California • New Haven, Connecticut • Naperville, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2019 · Synced Oct 16, 2026, 8:36 PM EDT
Completed Not applicable Interventional Results available

Treatment of Complicated Parapneumonic Effusion With Fibrinolytic Therapy Versus VATs Decortication

NCT03583931
View directory record Official record
Conditions
Parapneumonic Effusion, Empyema, Pleural, Coagulopathy
Interventions
VATS Decortication, Fibrinolytic Therapy
Procedure · Drug
Lead sponsor
Denver Health and Hospital Authority
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 27, 2022 · Synced Oct 16, 2026, 8:36 PM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability, and Efficacy of MN-001 (Tipelukast) in Patients With Idiopathic Pulmonary Fibrosis

NCT02503657
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis, IPF
Interventions
MN-001, Placebo
Drug
Lead sponsor
MediciNova
Industry
Eligibility
21 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 16, 2026, 8:36 PM EDT
Completed Phase 4 Interventional

Static Lung Hyperinflation and Sympathetic Nerve Activity-Associated Large Artery Stiffness in COPD Patients

NCT03611699
View directory record Official record
Conditions
COPD
Interventions
Umeclidinium / Vilanterol Dry Powder Inhaler, Placebo
Drug
Lead sponsor
Gary L. Pierce
Other
Eligibility
30 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jul 14, 2020 · Synced Oct 16, 2026, 8:36 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Improving Quality by Maintaining Accurate Problems in the EHR

NCT02596087
View directory record Official record
Conditions
Asthma, Atrial Fibrillation, Chronic Obstructive Pulmonary Disease, Coronary Artery Disease, Congestive Heart Failure, Hyperlipidemia, Hypertension, Myocardial Infarction, Sickle Cell Disease, Sleep Apnea, Smoking, Stroke, Tuberculosis
Interventions
Problem List Suggestion
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
2,386 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2016
U.S. locations
4
States / cities
Boston, Massachusetts • Portland, Oregon • Camp Hill, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Oct 16, 2026, 8:36 PM EDT
Completed Phase 4 Interventional Results available

Phase IV O2 Consumption Study in COPD Patients.

NCT02533505
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Budesonide 160 mcg and formoterol fumarate dihydrate 4.5 mcg Inhalation aerosol, Matching Placebo pMDI 160/4.5 μg
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 80 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
5
States / cities
Hartford, Connecticut • Boston, Massachusetts • Charlotte, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2018 · Synced Oct 16, 2026, 8:36 PM EDT
Recruiting Not applicable Interventional

Right Ventricular Response to Exercise Among Patients With Chronic Obstructive Pulmonary Disease

NCT07576894
View directory record Official record
Conditions
COPD, Pulmonary Hypertension, Exercise, Right Ventricular (RV) Dysfunction, Exercise Training
Interventions
Exercise training
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
40 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 16, 2026, 8:36 PM EDT
Recruiting Not applicable Interventional

Physiologic Effects of Nasal High Flow on Exercise Tolerance in COPD

NCT06578156
View directory record Official record
Conditions
COPD
Interventions
Nasal High Flow Cannula, Nasal Low Flow Cannula
Device
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 100 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 16, 2026, 8:36 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Effects of Treating Obese and Lean Patients With Sleep Apnea

NCT01578031
View directory record Official record
Conditions
Sleep Apnea, Obesity
Interventions
Positive Airway Pressure During Sleep (ResMed S9 Elite), Usual Care
Device · Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
40 Years to 65 Years
Enrollment
450 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 5, 2019 · Synced Oct 16, 2026, 8:36 PM EDT
Terminated Phase 3 Interventional

Apnex Clinical Study of the Hypoglossal Nerve Stimulation (HGNS®) System to Treat Obstructive Sleep Apnea

NCT01446601
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
Hypoglossal Nerve Stimulation (HGNS) System (Apnex Medical )
Device
Lead sponsor
Apnex Medical, Inc.
Industry
Eligibility
21 Years to 80 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
12
States / cities
Lenexa, Kansas • Topeka, Kansas • Louisville, Kentucky + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2015 · Synced Oct 16, 2026, 8:36 PM EDT
Completed Not applicable Interventional

Stepped Care vs Center-based Cardiopulmonary Rehabilitation for Older Frail Adults Living in Rural MA

NCT05562037
View directory record Official record
Conditions
Angina, Stable, Congestive Heart Failure, Chronic Obstructive Pulmonary Disease
Interventions
Stepped Care
Other
Lead sponsor
Peter Lindenauer, MD
Other
Eligibility
60 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
Pittsfield, Massachusetts • Springfield, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 24, 2025 · Synced Oct 16, 2026, 8:36 PM EDT
Completed No phase listed Observational

Urokinase Like Plasminogen Activator Levels in Patients Undergoing Bronchoscopy

NCT00929565
View directory record Official record
Conditions
Hemoptysis
Interventions
Not listed
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Apr 9, 2012 · Synced Oct 16, 2026, 8:36 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

"Anticipatory Guidance in the Nursery and Its Impact on Non-urgent Emergency Department Visits"

NCT01859065
View directory record Official record
Conditions
Health Knowledge, Attitudes, Practice, Sneezing, Constipation, Nasal Congestion and Inflammations
Interventions
Intensified anticipatory guidance, Routine
Behavioral
Lead sponsor
Bronx-Lebanon Hospital Center Health Care System
Other
Eligibility
Female only
Enrollment
323 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated May 21, 2013 · Synced Oct 16, 2026, 8:36 PM EDT